Adherium Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Paul Mastoridis

Algemeen directeur

AU$820.2k

Totale compensatie

Percentage CEO-salaris	31.0%
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	8.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul Mastoridis's beloning veranderd ten opzichte van Adherium's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$820k	AU$254k	-AU$10m

Compensatie versus markt: De totale vergoeding ($USD 539.12K ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 299.68K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Paul te vergelijken met de prestaties van het bedrijf.

CEO

Paul Mastoridis

less than a year

Tenure

AU$820,166

Compensatie

Dr. Paul Mastoridis is Chief Executive Officer of Adherium Limited from February 01, 2024. Paul Mastoridis has many years experience in the pharmaceutical industry, pioneering and leading digital solutions...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Louis Panaccio	Executive Chairman of the Board	2.8yrs	AU$110.50k	1.02% A$ 69.0k
Paul Mastoridis	Chief Executive Officer	less than a year	AU$820.17k	geen gegevens
Daniel Kaplon	Chief Financial Officer	2.1yrs	AU$314.99k	geen gegevens
Emily Austin	Company Secretary	less than a year	AU$130.02k	geen gegevens
Nilesh Ghatpande	VP of Engineering & Technology	less than a year	geen gegevens	geen gegevens
Cassandra Thomas	Vice President of People & Culture	less than a year	geen gegevens	geen gegevens
Michael Motion	Consultant	3.5yrs	AU$1.14m	geen gegevens
Zoe Park	Head of Software	less than a year	geen gegevens	geen gegevens
Nancy She	Head of Supply Chain and Procurement	less than a year	geen gegevens	geen gegevens
Michael Gormack	Head of Devices	less than a year	geen gegevens	geen gegevens
John Wilson	Executive Medical Director	8.2yrs	AU$12.71k	geen gegevens

0.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ADR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Louis Panaccio	Executive Chairman of the Board	2.8yrs	AU$110.50k	1.02% A$ 69.0k
Bruce McHarrie	Independent Non-Executive Director	9.3yrs	AU$55.25k	0.049% A$ 3.3k
William Hunter	Independent Non-Executive Director	8.9yrs	AU$50.00k	0.028% A$ 1.9k
Jeremy Curnock-Cook	Independent Non-Executive Director	9.6yrs	AU$50.00k	0.024% A$ 1.6k
George Baran	Non-Executive Director	3.5yrs	AU$50.00k	1% A$ 67.5k

8.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ADR wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.9 jaar).

Adherium Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Adherium Limited, Annual General Meeting, Nov 15, 2024

Adherium Limited, Annual General Meeting, Nov 30, 2023

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited, Annual General Meeting, Nov 29, 2022

Recent updates

Adherium Limited, Annual General Meeting, Nov 15, 2024

Full year 2024 earnings released: AU$0.014 loss per share (vs AU$0.036 loss in FY 2023)

New major risk - Revenue size

New major risk - Shareholder dilution

Adherium Limited has filed a Follow-on Equity Offering in the amount of AUD 1.57 million.

New major risk - Financial position

Forecast to breakeven in 2025

New major risk - Market cap size

Adherium Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Revenue size

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Limited Commences Production and Market Release of the New, Next Generation Ellipta Sensor

Adherium Limited Receives Australian Therapeutic Goods Administration Approval for Next Generation Sensors

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited Receives U.S. FDA 510(k) Clearance for GSK pMDI Inhaler Users to Remotely Monitor Physiological Parameters

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.017 loss in FY 2021)

Adherium Limited Submits FDA 510(K) Application for Next Generation Hailie Sensor for Teva MDI Inhalers

Adherium Limited Submits US FDA Application for Hailie for GSK pMDI inhalers

Adherium Limited Receives U.S. Food and Drug Administration Clearance for Hailie for Ellipta

Adherium Limited Announces Conclusion of Robert Spurr's Assignment as Interim CFO

Adherium Limited Releases Next Gen Platform Integration Services

Adherium Limited Submits US FDA 510(k) Application for Ellipta Inhaler Users to Connect to Hailie Platform with Physiological Parameters

Adherium Limited Announces Board Changes

Adherium Limited Announces That Manufacturing Started for Hailie® for Symbicort® Sensors with Physiological Parameters

Adherium Submits US FDS 510(k) Application for Next Generation Hailie Sensor with Physiological Measures

Adherium Limited announced that it expects to receive AUD 3 million in funding from Trudell Medical Limited, Bioscience Managers Pty Ltd

Independent Non-Executive Director has left the company

Adherium Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.036 loss per share

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd